As we predicted, an entirely new “vaccine” is going to be released to deal with this SUPER MUTANT nomad soul version of this completely fake virus that has never been proved to exist.
Who even knows what the new version will do?
I don’t know.
They can release it whenever they want because it’s a fake vaccine to deal with a fake disease.
BioNTech says it could produce and ship an updated version of its vaccine within 100 days if the new Covid variant detected in southern Africa is found to evade existing immunity.
The German biotechnology company is already investigating whether the vaccine it developed with US drugmaker Pfizer works well against the variant, named Omicron, which has caused concern due to its high number of mutations and initial suggestions that it could be transmitting more quickly.
The company says it will know in two weeks whether its current vaccine is likely to be sufficiently effective against the B.1.1.529 variant, now named Omicron by the World Health Organization, based on lab-based experiments.
If required, BioNTech said it is poised to tweak its vaccine to match it more closely to the new variant.
“Pfizer and BioNTech have taken actions months ago to be able to adapt the mRNA vaccine within six weeks and ship initial batches within 100 days in the event of an escape variant,” the company said in a statement.
The US company Moderna said it was testing three existing Covid-19 vaccine booster candidates against the Omicron variant, and that it would develop a new variant-specific booster against it.
“From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves. The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant,” said Stéphane Bancel, Moderna’s chief executive.
Other vaccine teams, including Johnson & Johnson, also confirmed on Friday that they were testing the effectiveness of their vaccines against the new variant to assess whether updates were likely to be required. AstraZeneca said it is already conducting research in Botswana and Eswatini, where the variant has been identified, to collect real-world data on how the Oxford/AstraZeneca vaccine performs against the new variant.
At the moment, concerns about a decline in protection are theoretical based on the very high number of mutations – double that seen in Delta – on the spike protein that the vaccine targets.
The single most shocking thing about this is that no one could have predicted it.